SOX7 Suppresses Wnt Signaling by Disrupting ß-Catenin/BCL9 Interaction.

The Wnt signaling is involved in angiogenesis and tumor development. ß-catenin is the core component of the Wnt pathway, which mediates oncogenic transcription and regulated by a series of proteins. Sex-determining region Y-box 7 (SOX7) is a member of high-mobility-group transcription factor family, which inhibits oncogenic Wnt signaling in lots of tumor cells with unknown mechanism. By coimmunoprecipitation (co-IP) and super Topflash reporter assay, SOX7 can bind ß-catenin and inhibit ß-catenin/T cell factor (TCF)-mediated transcription. Meanwhile, B cell lymphoma 9 (BCL9) drives Wnt signaling path through direct binding-mediated ß-catenin. Finally, we found that SOX7 inhibits oncogenic ß-catenin-mediated transcription by disrupting the ß-catenin/BCL9 interaction. Mechanistically, SOX7 compete with BCL9 to bind ß-catenin. Our results show SOX7 inhibited Wnt signaling as suppressor and could be an important target for anticancer therapy.

[Effects of the Chinese patent medicine, Honghua Injection, on platelet glycoprotein IIb/III a receptors in patients with acute coronary syndrome: a randomized controlled trial].

BACKGROUND: Glycoprotein (GP) IIb/IIIa is an important index for assessing the function of platelets. To investigate the effects of Honghua Injection, a Chinese patent medicine made from extracts of Carthamus tinctorius L, on GP IIb/IIIa is a key study in evaluating the inhibition properties of Honghua Injection on platelet aggregation. OBJECTIVE: To observe the effects of Honghua Injection on platelet GPIIb/IIIa receptors and explore the mechanisms of Honghua Injection in inhibiting platelet aggregation in patients with acute coronary syndrome. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 64 patients from Yueyang Hospital of Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine were randomly divided into Honghua Injection group (n=32, routine Western medicine plus Honghua Injection) and control group (n=32, routine Western medicine) according to the random number table. The patients were treated for 14 d. MAIN OUTCOME MEASURES: The expressions of GPIIb/IIIa (CD41), P-selection (CD62p), and lysosome-associated membrane GP (CD63) were measured by flow cytometry before and after treatment. Meanwhile the therapeutic effects of Huonghua Injection on angina and short-term prognosis were observed. RESULTS: The observational period was 14 d and four patients in the control group were omitted due to early discharge. The expression of CD41 in both the Honghua Injection group and the control group was inhibited after treatment (P<0.05, P<0.01). The inhibition of the Honghua Injection group was stronger than that of the control group (P<0.05). There was no case of death, myocardial infarction and cerebral apoplexy during 14 d of treatment. The improvement of angina symptoms and electrocardiographic manifestation in the Honghua Injection group was greater than that of the control group (P<0.05). CONCLUSION: Honghua Injection can inhibit the expression of GP IIb/IIIa receptors by preventing aggregation of platelets and may be considered as an effective traditional Chinese medicine for acute coronary syndrome.